Table 1.

Characteristics of subjects at baseline and 12 months after metreleptin treatment in the RLD study (n = 9)

Parameters	Baseline	Month 12	P value
Body weight (kg)	90.9 ± 8.7	86.8 ± 9.3	0.012
Total fat mass (kg)	24.9 ± 5.3	22.5 ± 4.9	0.048
Total lean mass (kg)	62.5 ± 5.8	61.0 ± 5.4	0.010
Leptin (ng/mL)	7.0 ± 2.4	127.5 ± 87	0.003
Glucose (mg/dL)	100 ± 10	95 ± 11	0.038
Triglycerides (mg/dL)	129 ± 66	148 ± 69	0.440
HOMA-IR	7.43 ± 3.16	5.45 ± 2.17	0.097
FFA (mEq/L)	0.44 ± 0.15	0.55 ± 0.31	0.414
REE (kcal)	1746 ± 307	1795 ± 247	0.475
RQ	0.80 ± 0.05	0.80 ± 0.05	0.710
Adiponectin (μg/mL)	6.44 ± 2.35	6.42 ± 2.32	0.962
GIP (pg/mL)	52.68 ± 37.29	27.77 ± 7.60	0.044
GLP-1 (pg/mL)	4.81 ± 2.16	4.62 ± 1.83	0.420
Ghrelin (pg/mL)	645.26 ± 497.24	786.20 ± 457.40	0.256
IL-6 (ng/mL)	1.71 ± 1.20	1.34 ± 0.99	0.373
sLEPR (ng/mL)	19.90 ± 6.1	19.83 ± 4.84	0.957

Mean ± SD values are shown (even for non-normally distributed data). P values are calculated by using a paired sample t-test. Log transformation was applied if needed. FFA: Free fatty acids, HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, GIP: glucose-dependent insulinotropic peptide, GLP-1: Glucagon-like peptide 1, REE: Resting energy expenditure, RQ: Respiratory quotient, sLEPR: soluble leptin receptor.